Cervical Cancer Test Market & Screening Population Analysis, By Screening Type (Pap Smear, HPV DNA, VIA) - Global Forecast to 2022

Publisher Name :
Date: 24-Jul-2017
No. of pages: 306

Cervical cancer is one of the most prevalent forms of cancer affecting women all over the world. In most cases, the disease is attributed to genital Human Papilloma Virus (HPV) infection. As cervical cancer is a disease with long latent period, early detection and treatment of precancerous lesions is known to be highly effective in women who regularly participate in screening programs. The death rate due to cervical cancer has dropped in many developed countries, thus indicating the growing adoption of screening procedures, such as Pap test and HPV testing.

The cervical cancer test market is driven by growth in aging female population and rising prevalence rate of cervical cancer, high incidence rate of HPV infections, rising incidences of teenage sexual cases, increasing number of awareness programs for cervical cancer screening, introduction of low cost VIA test and government initiatives and funding. However, lack of healthcare infrastructure and awareness regarding cervical cancer screening are the major restraints for cervical cancer testing market.

Key Highlights of the Report


  • Cervical cancer is amongst one of the most common causes of deaths in the U.S. women. United States alone captured over 40 percent share of the global cervical cancer test market.

  • Pap test held a majority share of the cervical cancer screening market on account of the high efficiency of this test, however, HPV test is steadily gaining prominence.

  • VIA is the best screening option where access to Pap smear tests and HPV test is not available.

  • In 2016, Global cervical cancer test population was estimated at XXX Million.

  • Cervical cancer incidence rate in Europe is estimated at 10.6 per 100,000 women population.

  • Asia Pacific and North American region are competing closely with each other to grab maximum share of the cervical cancer test population.

  • Indonesia, China, India and Japan captures highest share of the Asian cervical cancer test population.

  • North America captures highest share of the global cervical cancer test market followed by the European region.

  • Germany, United Kingdom and France are the other top three leaders in cervical cancer test market.

  • China and India are the top contributor to the VIA test market.

  • Australia’s National Cervical Cancer Screening Program will change from December 2017.


iGATE RESEARCH report titled “Cervical Cancer Test Market & Screening Population Analysis, By Screening Type (Pap Smear, HPV DNA, VIA) - Global Forecast to 2022” is a 306 Page report with 238 Figures and 25 Tables. This report provides a comprehensive assessment of the Cervical Cancer Test (Pap Smear, HPV DNA Test and VIA) Screening Market in terms of Value and Volume terms.

The 20 Countries covered in the report have been analyzed from 4 View Points:


  • Cervical Cancer Test Population (2007 - 2022)

    • Pap Smear Test Population (2007 - 2022)

    • HPV DNA Test population (2007 - 2022)

    • VIA Test Population (2007 - 2022)



  • Cervical Cancer Mortality

  • Cervical Cancer Test Market (2007 - 2022)

    • Pap Smear Test Market (2007 - 2022)

    • HPV DNA Test Market (2007 - 2022)

    • VIA Test Market (2007 - 2022)



  • Global Cervical Cancer Test Market - Driving Factors and Challenges


Cervical Cancer Test Market & Screening Population Analysis - 20 Countries Covered


  • United States

  • Canada

  • United Kingdom

  • France

  • Germany

  • Italy

  • Spain

  • Sweden

  • Switzerland

  • Norway

  • Netherlands

  • Japan

  • South Korea

  • Singapore

  • Malaysia

  • Australia

  • India

  • China

  • Thailand

  • Indonesia


Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Cervical Cancer Test Market & Screening Population Analysis, By Screening Type (Pap Smear, HPV DNA, VIA) - Global Forecast to 2022

Table of Contents

1. Executive Summary

2. Global Cervical Cancer Test (Screening) Population & Forecast (2007 - 2022)
2.1 By Region - Cervical Cancer Test (Screening) Population & Forecast
2.1.1 North America Cervical Cancer Test (Screening) Population & Forecast
2.1.2 Europe Cervical Cancer Test (Screening) Population & Forecast
2.1.3 Asia Pacific Cervical Cancer Test (Screening) Population & Forecast

3. Global Cervical Cancer Test (Screening) Market & Forecast (2007 - 2022)
3.1 By Region - Cervical Cancer Test (Screening) Market & Forecast
3.1.1 North America Cervical Cancer Test (Screening) Market & Forecast
3.1.2 Europe Cervical Cancer Test (Screening) Market & Forecast
3.1.3 Asia Pacific Cervical Cancer Test (Screening) Market & Forecast

4. Global Cervical Cancer Test (Screening) Market & Forecast (2007 - 2022) - By Segment
4.1 Global Cervical Cancer Pap Smear Test (Screening) Market & Forecast
4.2 Global Cervical Cancer HPV DNA Test (Screening) Market & Forecast
4.3 Global Cervical Cancer Visual Inspection with Acetic Acid (VIA) Test (Screening) Market & Forecast

5. Cervical Cancer Test (Screening) Population Share & Forecast (2007 - 2022)
5.1 Global Cervical Cancer Test (Screening) Population Share & Forecast - Regional Analysis
5.2 Global Cervical Cancer Test (Screening) Population Share & Forecast - Country Wise Analysis

6. Global Cervical Cancer Test (Screening) Market Share & Forecast (2007 - 2022)
6.1 Global Cervical Cancer Test (Screening) Market Share & Forecast - Regional Analysis
6.2 Global Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis
6.3 Global Pap Smear Test (Screening) Market Share & Forecast - Country Wise Analysis
6.4 Global HPV DNA Test (Screening) Market Share & Forecast - Country Wise Analysis
6.5 Global VIA Test (Screening) Market Share & Forecast - Country Wise Analysis
6.6 By Region - Cervical Cancer Test (Screening) Market & Forecast
6.6.1 North America Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis
6.6.2 Europe Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis
6.6.3 Asia Pacific Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis

7. United States - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
7.1 United States Cervical Cancer Test (Screening) Population and Forecast
7.1.1 United States Cervical Cancer Pap Smear Test Population & Forecast
7.1.2 United States Cervical Cancer HPV DNA Test Population & Forecast
7.2 United States Cervical Cancer Mortality
7.3 United States Cervical Cancer Test (Screening) Market and Forecast
7.3.1 United States Cervical Cancer Pap Smear Test Market & Forecast
7.3.2 United States Cervical Cancer HPV DNA Test Market & Forecast

8. Canada - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
8.1 Canada Cervical Cancer Test (Screening) Population and Forecast
8.1.1 Canada Cervical Cancer Pap Smear Test Population & Forecast
8.1.2 Canada Cervical Cancer HPV DNA Test Population & Forecast
8.2 Canada Cervical Cancer Mortality
8.3 Canada Cervical Cancer Test (Screening) Market and Forecast
8.3.1 Canada Cervical Cancer Pap Smear Test Market & Forecast
8.3.2 Canada Cervical Cancer HPV DNA Test Market & Forecast

9. United Kingdom - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
9.1 United Kingdom Cervical Cancer Test (Screening) Population and Forecast
9.1.1 United Kingdom Cervical Cancer Pap Smear Test Population & Forecast
9.1.2 United Kingdom Cervical Cancer HPV DNA Test Population & Forecast
9.2 United Kingdom Cervical Cancer Mortality
9.3 United Kingdom Cervical Cancer Test (Screening) Market and Forecast
9.3.1 United Kingdom Cervical Cancer Pap Smear Test Market & Forecast
9.3.2 United Kingdom Cervical Cancer HPV DNA Test Market & Forecast

10. France - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
10.1 France Cervical Cancer Test (Screening) Population and Forecast
10.1.1 France Cervical Cancer Pap Smear Test Population & Forecast
10.1.2 France Cervical Cancer HPV DNA Test Population & Forecast
10.2 France Cervical Cancer Test (Screening) Market and Forecast
10.2.1 France Cervical Cancer Pap Smear Test Market & Forecast
10.2.2 France Cervical Cancer HPV DNA Test Market & Forecast

11. Germany - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
11.1 Germany Cervical Cancer Test (Screening) Population and Forecast
11.1.1 Germany Cervical Cancer Pap Smear Test Population & Forecast
11.1.2 Germany Cervical Cancer HPV DNA Test Population & Forecast
11.2 Germany Cervical Cancer Test (Screening) Market and Forecast
11.2.1 Germany Cervical Cancer Pap Smear Test Market & Forecast
11.2.2 Germany Cervical Cancer HPV DNA Test Market & Forecast

12. Italy - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
12.1 Italy Cervical Cancer Test (Screening) Population and Forecast
12.1.1 Italy Cervical Cancer Pap Smear Test Population & Forecast
12.1.2 Italy Cervical Cancer HPV DNA Test Population & Forecast
12.2 Italy Cervical Cancer Test (Screening) Market and Forecast
12.2.1 Italy Cervical Cancer Pap Smear Test Market & Forecast
12.2.2 Italy Cervical Cancer HPV DNA Test Market & Forecast

13. Spain - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
13.1 Spain Cervical Cancer Test (Screening) Population and Forecast
13.1.1 Spain Cervical Cancer Pap Smear Test Population & Forecast
13.1.2 Spain Cervical Cancer HPV DNA Test Population & Forecast
13.2 Spain Cervical Cancer Test (Screening) Market and Forecast
13.2.1 Spain Cervical Cancer Pap Smear Test Market & Forecast
13.2.2 Spain Cervical Cancer HPV DNA Test Market & Forecast

14. Sweden - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
14.1 Sweden Cervical Cancer Test (Screening) Population and Forecast
14.1.1 Sweden Cervical Cancer Pap Smear Test Population & Forecast
14.1.2 Sweden Cervical Cancer HPV DNA Test Population & Forecast
14.2 Sweden Cervical Cancer Test (Screening) Market and Forecast
14.2.1 Sweden Cervical Cancer Pap Smear Test Market & Forecast
14.2.2 Sweden Cervical Cancer HPV DNA Test Market & Forecast

15. Switzerland - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
15.1 Switzerland Cervical Cancer Test (Screening) Population and Forecast
15.1.1 Switzerland Cervical Cancer Pap Smear Test Population & Forecast
15.1.2 Switzerland Cervical Cancer HPV DNA Test Population & Forecast
15.2 Switzerland Cervical Cancer Test (Screening) Market and Forecast
15.2.1 Switzerland Cervical Cancer Pap Smear Test Market & Forecast
15.2.2 Switzerland Cervical Cancer HPV DNA Test Market & Forecast

16. Norway - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
16.1 Norway Cervical Cancer Test (Screening) Population and Forecast
16.1.1 Norway Cervical Cancer Pap Smear Test Population & Forecast
16.1.2 Norway Cervical Cancer HPV DNA Test Population & Forecast
16.2 Norway Cervical Cancer Test (Screening) Market and Forecast
16.2.1 Norway Cervical Cancer Pap Smear Test Market & Forecast
16.2.2 Norway Cervical Cancer HPV DNA Test Market & Forecast

17. Netherlands - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
17.1 Netherlands Cervical Cancer Test (Screening) Population and Forecast
17.1.1 Netherlands Cervical Cancer Pap Smear Test Population & Forecast
17.1.2 Netherlands Cervical Cancer HPV DNA Test Population & Forecast
17.2 Netherlands Cervical Cancer Test (Screening) Market and Forecast
17.2.1 Netherlands Cervical Cancer Pap Smear Test Market & Forecast
17.2.2 Netherlands Cervical Cancer HPV DNA Test Market & Forecast

18. Japan - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
18.1 Japan Cervical Cancer Test (Screening) Population and Forecast
18.1.1 Japan Cervical Cancer Pap Smear Test Population & Forecast
18.1.2 Japan Cervical Cancer HPV DNA Test Population & Forecast
18.2 Japan Cervical Cancer Test (Screening) Market and Forecast
18.2.1 Japan Cervical Cancer Pap Smear Test Market & Forecast
18.2.2 Japan Cervical Cancer HPV DNA Test Market & Forecast

19. South Korea - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
19.1 South Korea Cervical Cancer Test (Screening) Population and Forecast
19.1.1 South Korea Cervical Cancer Pap Smear Test Population & Forecast
19.1.2 South Korea Cervical Cancer HPV DNA Test Population & Forecast
19.2 South Korea Cervical Cancer Mortality
19.3 South Korea Cervical Cancer Test (Screening) Market and Forecast
19.3.1 South Korea Cervical Cancer Pap Smear Test Market & Forecast
19.3.2 South Korea Cervical Cancer HPV DNA Test Market & Forecast

20. Singapore - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
20.1 Singapore Cervical Cancer Test (Screening) Population and Forecast
20.1.1 Singapore Cervical Cancer Pap Smear Test Population & Forecast
20.1.2 Singapore Cervical Cancer HPV DNA Test Population & Forecast
20.2 Singapore Cervical Cancer Test (Screening) Market and Forecast
20.2.1 Singapore Cervical Cancer Pap Smear Test Market & Forecast
20.2.2 Singapore Cervical Cancer HPV DNA Test Market & Forecast

21. Malaysia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
21.1 Malaysia Cervical Cancer Test (Screening) Population and Forecast
21.1.1 Malaysia Cervical Cancer Pap Smear Test Population & Forecast
21.1.2 Malaysia Cervical Cancer HPV DNA Test Population & Forecast
21.2 Malaysia Cervical Cancer Test (Screening) Market and Forecast
21.2.1 Malaysia Cervical Cancer Pap Smear Test Market & Forecast
21.2.2 Malaysia Cervical Cancer HPV DNA Test Market & Forecast

22. India - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
22.1 India Cervical Cancer Test (Screening) Population and Forecast
22.1.1 India Cervical Cancer Pap Smear Test Population & Forecast
22.1.2 India Cervical Cancer HPV DNA Test Population & Forecast
22.1.3 India Cervical Cancer VIA Test Population & Forecast
22.2 India Cervical Cancer Test (Screening) Market and Forecast
22.2.1 India Cervical Cancer Pap Smear Test Market & Forecast
22.2.2 India Cervical Cancer HPV DNA Test Market & Forecast
22.2.3 India Cervical Cancer VIA Test Market & Forecast

23. China - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
23.1 China Cervical Cancer Test (Screening) Population and Forecast
23.1.1 China Cervical Cancer Pap Smear Test Population & Forecast
23.1.2 China Cervical Cancer HPV DNA Test Population & Forecast
23.1.3 China Cervical Cancer VIA Test Population & Forecast
23.2 China Cervical Cancer Test (Screening) Market and Forecast
23.2.1 China Cervical Cancer Pap Smear Test Market & Forecast
23.2.2 China Cervical Cancer HPV DNA Test Market & Forecast
23.2.3 China Cervical Cancer VIA Test Market & Forecast

24. Thailand - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
24.1 Thailand Cervical Cancer Test (Screening) Population and Forecast
24.1.1 Thailand Cervical Cancer Pap Smear Test Population & Forecast
24.1.2 Thailand Cervical Cancer VIA Test Population & Forecast
24.2 Thailand Cervical Cancer Test (Screening) Market and Forecast
24.2.1 Thailand Cervical Cancer Pap Smear Test Market & Forecast
24.2.2 Thailand Cervical Cancer VIA Test Market & Forecast

25. Indonesia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
25.1 Indonesia Cervical Cancer Test (Screening) Population and Forecast
25.1.1 Indonesia Cervical Cancer Pap Smear Test Population & Forecast
25.1.2 Indonesia Cervical Cancer HPV DNA Test Population & Forecast
25.1.3 Indonesia Cervical Cancer VIA Test Population & Forecast
25.1.4 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Population & Forecast
25.2 Indonesia Cervical Cancer Test (Screening) Market and Forecast
25.2.1 Indonesia Cervical Cancer Pap Smear Test Market & Forecast
25.2.2 Indonesia Cervical Cancer HPV DNA Test Market & Forecast
25.2.3 Indonesia Cervical Cancer VIA Test Market & Forecast
25.2.4 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Market & Forecast

26. Australia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2017)
26.1 Australia Cervical Cancer Test (Screening) Population and Forecast
26.1.1 Australia Cervical Cancer Pap Smear Test Population & Forecast
26.1.2 Australia Cervical Cancer HPV DNA Test Population & Forecast
26.2 Australia Cervical Cancer Mortality
26.3 Australia Cervical Cancer Test (Screening) Market and Forecast
26.3.1 Australia Cervical Cancer Pap Smear Test Market & Forecast
26.3.2 Australia Cervical Cancer HPV DNA Test Market & Forecast

27. Cervical Cancer Test (Screening) Market - Driving Factors
27.1 Introduction of Low Cost VIA Test
27.1.1 Countries Offering VIA Test via National Programs
27.1.2 Countries Offering VIA Test via Pilot Programs
27.2 High Prevalence of HPV Infected Patients Globally
27.3 Rising Incidence of Teenage Sexual Cases Globally

28. Cervical Cancer Test (Screening) Market - Challenges
28.1 Lack of Appropriate Healthcare Infrastructure
28.2 Introduction of HPV Vaccination Programs Worldwide

List of Tables:

Table 5-1: By Region - Cervical Cancer Test Population Share (Percent), 2007 - 2016
Table 5-2: By Region - Forecast for Cervical Cancer Test Population Share (Percent), 2017 - 2022
Table 5-3: Global - Cervical Cancer Test Population Share (Percent), 2007 - 2016
Table 5-4: Global - Forecast for Cervical Cancer Test Population Share (Percent), 2017 - 2022
Table 6-1: By Region - Cervical Cancer Test Market Share (Percent), 2007 - 2016
Table 6-2: By Region - Forecast for Cervical Cancer Test Market Share (Percent), 2017 - 2022
Table 6-3: Global - Cervical Cancer Test Market Share (Percent), 2007 - 2016
Table 6-4: Global - Forecast for Cervical Cancer Test Market Share (Percent), 2017 - 2022
Table 6-5: Global - Cervical Cancer Pap Smear Test Market Share (Percent), 2007 - 2016
Table 6-6: Global - Forecast for Cervical Cancer Pap Smear Test Market Share (Percent), 2017 - 2022
Table 6-7: Global - Cervical Cancer HPV DNA Test Market Share (Percent), 2007 - 2016
Table 6-8: Global - Forecast for Cervical Cancer HPV DNA Test Market Share (Percent), 2017 - 2022
Table 6-9: Global - Cervical Cancer VIA Test Market Share (Percent), 2007 - 2016
Table 6-10: Global - Forecast for Cervical Cancer VIA Test Market Share (Percent), 2017 - 2022
Table 6-11: North America - Cervical Cancer Test Market Share (Percent), 2007 - 2016
Table 6-12: North America - Forecast for Cervical Cancer Test Market Share (Percent), 2017 - 2022
Table 6-13: Europe - Cervical Cancer Test Market Share (Percent), 2007 - 2016
Table 6-14: Europe - Forecast for Cervical Cancer Test Market Share (Percent), 2017 - 2022
Table 6-15: Asia Pacific - Cervical Cancer Test Market Share (Percent), 2007 - 2016
Table 6-16: Asia Pacific - Forecast for Cervical Cancer Test Market Share (Percent), 2017 - 2022
Table 9-1: United Kingdom - HPV Testing by Country
Table 27-1: Worldwide - List of Countries which offer VIA Test via National Programs, 2010
Table 27-2: Worldwide - List of Countries which offer VIA Test via Pilot Programs, 2010
Table 27-3: Worldwide - HPV Prevalence (Percent) among Women with Normal Cervical Cytology, 2010
Table 27-4: Worldwide - Prevalence (Percent) of Young Women (15-44 Years) who Have Sex before the Age of 15 Years, 1994 - 2006

List of Figures:

Figure 2-1: Global - Cervical Cancer Test Population (Million), 2007 - 2016
Figure 2-2: Global - Forecast for Cervical Cancer Test Population (Million), 2017 - 2022
Figure 2-3: North America - Cervical Cancer Test Population (Million), 2007 - 2016
Figure 2-4: North America - Forecast for Cervical Cancer Test Population (Million), 2017 - 2022
Figure 2-5: Europe - Cervical Cancer Test Population (Million), 2007 - 2016
Figure 2-6: Europe - Forecast for Cervical Cancer Test Population (Million), 2017 - 2022
Figure 2-7: Asia Pacific - Cervical Cancer Test Population (Million), 2007 - 2016
Figure 2-8: Asia Pacific - Forecast for Cervical Cancer Test Population (Million), 2017 - 2022
Figure 3-1: Global - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 3-2: Global - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 3-3: North America - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 3-4: North America - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 3-5: Europe - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 3-6: Europe - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 3-7: Asia Pacific - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 3-8: Asia Pacific - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 4-1: Global - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 4-2: Global - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 4-3: Global - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 4-4: Global - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 4-5: Global - Cervical Cancer VIA Test Market (Million US$), 2007 - 2016
Figure 4-6: Global - Forecast for Cervical Cancer VIA Test Market (Million US$), 2017 - 2022
Figure 7-1: United States - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 7-2: United States - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 7-3: United States - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 7-4: United States - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 7-5: United States - Cervical Cancer Mortality (Number), 2010 - 2017
Figure 7-6: United States - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 7-7: United States - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 7-8: United States - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 7-9: United States - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 7-10: United States - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 7-11: United States - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 8-1: Canada - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 8-2: Canada - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 8-3: Canada - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 8-4: Canada - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 8-5: Canada - Cervical Cancer Mortality (Number), 2010 - 2017
Figure 8-6: Canada - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 8-7: Canada - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 8-8: Canada - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 8-9: Canada - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 8-10: Canada - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 8-11: Canada - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 9-1: United Kingdom - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 9-2: United Kingdom - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 9-3: United Kingdom - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 9-4: United Kingdom - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 9-5: United Kingdom - Cervical Cancer Mortality (Number), 2001 - 2014
Figure 9-6: United Kingdom - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 9-7: United Kingdom - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 9-8: United Kingdom - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 9-9: United Kingdom - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 9-10: United Kingdom - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 9-11: United Kingdom - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 10-1: France - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 10-2: France - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 10-3: France - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 10-4: France - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 10-5: France - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 10-6: France - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 10-7: France - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 10-8: France - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 10-9: France - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 10-10: France - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 11-1: Germany - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 11-2: Germany - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 11-3: Germany - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 11-4: Germany - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 11-5: Germany - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 11-6: Germany - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 11-7: Germany - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 11-8: Germany - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 11-9: Germany - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 11-10: Germany - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 12-1: Italy - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 12-2: Italy - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 12-3: Italy - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 12-4: Italy - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 12-5: Italy - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 12-6: Italy - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 12-7: Italy - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 12-8: Italy - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 12-9: Italy - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 12-10: Italy - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 13-1: Spain - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 13-2: Spain - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 13-3: Spain - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 13-4: Spain - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 13-5: Spain - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 13-6: Spain - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 13-7: Spain - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 13-8: Spain - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 13-9: Spain - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 13-10: Spain - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 14-1: Sweden - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 14-2: Sweden - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 14-3: Sweden - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 14-4: Sweden - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 14-5: Sweden - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 14-6: Sweden - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 14-7: Sweden - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 14-8: Sweden - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 14-9: Sweden - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 14-10: Sweden - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 15-1: Switzerland - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 15-2: Switzerland - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 15-3: Switzerland - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 15-4: Switzerland - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 15-5: Switzerland - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 15-6: Switzerland - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 15-7: Switzerland - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 15-8: Switzerland - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 15-9: Switzerland - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 15-10: Switzerland - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 16-1: Norway - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 16-2: Norway - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 16-3: Norway - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 16-4: Norway - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 16-5: Norway - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 16-6: Norway - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 16-7: Norway - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 16-8: Norway - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 16-9: Norway - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 16-10: Norway - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 17-1: Netherlands - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 17-2: Netherlands - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 17-3: Netherlands - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 17-4: Netherlands - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 17-5: Netherlands - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 17-6: Netherlands - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 17-7: Netherlands - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 17-8: Netherlands - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 17-9: Netherlands - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 17-10: Netherlands - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 18-1: Japan - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 18-2: Japan - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 18-3: Japan - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 18-4: Japan - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 18-5: Japan - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 18-6: Japan - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 18-7: Japan - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 18-8: Japan - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 18-9: Japan - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 18-10: Japan - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 19-1: South Korea - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 19-2: South Korea - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 19-3: South Korea - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 19-4: South Korea - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 19-5: South Korea - Cervical Cancer Mortality (Number), 2009 - 2013
Figure 19-6: South Korea - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 19-7: South Korea - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 19-8: South Korea - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 19-9: South Korea - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 19-10: South Korea - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 19-11: South Korea - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 20-1: Singapore - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 20-2: Singapore - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 20-3: Singapore - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 20-4: Singapore - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 20-5: Singapore - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 20-6: Singapore - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 20-7: Singapore - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 20-8: Singapore - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 20-9: Singapore - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 20-10: Singapore - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 21-1: Malaysia - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 21-2: Malaysia - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 21-3: Malaysia - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 21-4: Malaysia - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 21-5: Malaysia - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 21-6: Malaysia - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 21-7: Malaysia - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 21-8: Malaysia - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 21-9: Malaysia - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 21-10: Malaysia - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 22-1: India - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 22-2: India - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 22-3: India - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 22-4: India - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 22-5: India - Cervical Cancer VIA Test Population (Thousand), 2007 - 2016
Figure 22-6: India - Forecast for Cervical Cancer VIA Test Population (Thousand), 2017 - 2022
Figure 22-7: India - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 22-8: India - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 22-9: India - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 22-10: India - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 22-11: India - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 22-12: India - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 22-13: India - Cervical Cancer VIA Test Market (Million US$), 2007 - 2016
Figure 22-14: India - Forecast for Cervical Cancer VIA Test Market (Million US$), 2017 - 2022
Figure 23-1: China - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 23-2: China - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 23-3: China - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 23-4: China - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 23-5: China - Cervical Cancer VIA Test Population (Thousand), 2007 - 2016
Figure 23-6: China - Forecast for Cervical Cancer VIA Test Population (Thousand), 2017 - 2022
Figure 23-7: China - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 23-8: China - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 23-9: China - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 23-10: China - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 23-11: China - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 23-12: China - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 23-13: China - Cervical Cancer VIA Test Market (Million US$), 2007 - 2016
Figure 23-14: China - Forecast for Cervical Cancer VIA Test Market (Million US$), 2017 - 2022
Figure 24-1: Thailand - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 24-2: Thailand - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 24-3: Thailand - Cervical Cancer VIA Test Population (Thousand), 2007 - 2016
Figure 24-4: Thailand - Forecast for Cervical Cancer VIA Test Population (Thousand), 2017 - 2022
Figure 24-5: Thailand - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 24-6: Thailand - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 24-7: Thailand - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 24-8: Thailand - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 24-9: Thailand - Cervical Cancer VIA Test Market (Million US$), 2007 - 2016
Figure 24-10: Thailand - Forecast for Cervical Cancer VIA Test Market (Million US$), 2017 - 2022
Figure 25-1: Indonesia - Cervical Cancer Pap Smear Test Population (Thousand), 2007 - 2016
Figure 25-2: Indonesia - Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2017 - 2022
Figure 25-3: Indonesia - Cervical Cancer HPV DNA Test Population (Thousand), 2007 - 2016
Figure 25-4: Indonesia - Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2017 - 2022
Figure 25-5: Indonesia - Cervical Cancer VIA Test Population (Thousand), 2007 - 2016
Figure 25-6: Indonesia - Forecast for Cervical Cancer VIA Test Population (Thousand), 2017 - 2022
Figure 25-7: Indonesia - Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2007 - 2016
Figure 25-8: Indonesia - Forecast for Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2017 - 2022
Figure 25-9: Indonesia - Cervical Cancer Test Market (Million US$), 2007 - 2016
Figure 25-10: Indonesia - Forecast for Cervical Cancer Test Market (Million US$), 2017 - 2022
Figure 25-11: Indonesia - Cervical Cancer Pap Smear Test Market (Million US$), 2007 - 2016
Figure 25-12: Indonesia - Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2017 - 2022
Figure 25-13: Indonesia - Cervical Cancer HPV DNA Test Market (Million US$), 2007 - 2016
Figure 25-14: Indonesia - Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2017 - 2022
Figure 25-15: Indonesia - Cervical Cancer VIA Test Market (Million US$), 2007 - 2016
Figure 25-16: Indonesia - Forecast for Cervical Cancer VIA Test Market (Million US$), 2017 - 2022
Figure 25-17: Indonesia - Cervical Cancer Both (Pap Smear & VIA) Test Market (Million US$), 2007 - 2016
Figure 25-18: Indonesia - Forecast for Cervical Cancer Both (Pap Smear & VIA) Test Market (Million US$), 2017 - 2022
Figure 26-1: Australia - Cervical Cancer Pap Smear Test Population and Forecast (Thousand), 2007 - 2017
Figure 26-2: Australia - Cervical Cancer HPV DNA Test Population and Forecast (Thousand), 2007 - 2017
Figure 26-3: Australia - Cervical Cancer Mortality (Number), 2001 - 2017
Figure 26-4: Australia - Cervical Cancer Test Market and Forecast (Million US$), 2007 - 2017
Figure 26-5: Australia - Cervical Cancer Pap Smear Test Market and Forecast (Million US$), 2007 - 2017
Figure 26-6: Australia - Cervical Cancer HPV DNA Test Market and Forecast (Million US$), 2007 - 2017

  • Global Cancer Diagnostics Market Research Report 2017
    Published: 20-Nov-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Cancer Diagnostics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cancer Diagnostics in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China ......
  • EMEA Prostate Cancer Diagnostics Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 16-Nov-2017        Price: US 4480 Onwards        Pages: 119
    "The prostate is a walnut-sized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and......
  • Cancer Diagnostics Market 2021: Supplier Shares and Segment Sales Forecasts by Country, Competitive Profiles, Emerging Markers, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 7500 Onwards        Pages: 0
    This new report from VPGMarketResearch.com provides analysis of the global cancer diagnostics market, including emerging tests, technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers. The report presents:Estimated numbers of cancer testing laboratories, as well as test volume and sales forecasts for France, Germany, Italy, Japan, Spain, U.K. and U.S.Marketing and technological assessment, as well as medical rati......
  • Tumor Markers and Special Chemistry Market 2021: Supplier Shares, Competitive Strategies, Country Segment Forecasts, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 8500 Onwards        Pages: 0
    Complete report $8,500. DataPack (test volumes, sales forecasts, supplier shares) $5,500.This new 320-page report from VPGMarketResearch.com contains 83 tables and provides analysis of the global tumor markers and special chemistry testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts b......
  • Global Checkpoint Inhibitors for Treating Cancer Market Research Report 2017
    Published: 10-Nov-2017        Price: US 2900 Onwards        Pages: 100
    In this report, the global Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Checkpoint Inhibitors for Treating Cancer in these regions, from 2012 to 2022 (forecast), covering - North......
  • Global and Regional HPV Testing Market Research Report 2017
    Published: 08-Nov-2017        Price: US 3500 Onwards        Pages: 134
    Summary The human papillomavirus (HPV) test detects the presence of human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The HPV testing is further classified into three sub-segments, namely, follow-up testing, co-testing, HPV primary testing. Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle Ea......
  • Global Cancer Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts
    Published: 01-Nov-2017        Price: US 2995 Onwards        Pages: 700
    "Delivery of this report will take 1-3 days after purchase." The Global Cancer Diagnostics Partnering 2010-2017 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer diagnostics partnering contract doc......
  • Pancreatic Cancer Diagnostics Using Artificial Intelligence for Hospitals: Market Shares, Strategies, and Forecasts, Worldwide, 2017 to 2023
    Published: 25-Oct-2017        Price: US 4200 Onwards        Pages: 75
    The 2017 study has 75 pages, 28 tables and figures. Worldwide markets are poised to achieve continuing growth as the artificial intelligence software increases diagnostic excellence, saving lives and lowering care delivery costs. Automated cancer diagnostics are implemented with artificial intelligence. Systems are able to take a multi-disciplinary integrated approach to looking at imaging and scans. The analysis of patient records, looking for effectiveness of particular treatments i......
  • Global and Regional Checkpoint Inhibitors for Treating Cancer Market Research Report 2017
    Published: 24-Oct-2017        Price: US 3500 Onwards        Pages: 126
    Summary Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the "brakes" on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs